Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) Director Sol J. Barer purchased 421,032 shares of the stock in a transaction that occurred on Tuesday, October 17th. The shares were bought at an average cost of $1.26 per share, for a total transaction of $530,500.32. Following the acquisition, the director now owns 1,028,032 shares of the company’s stock, valued at $1,295,320.32. The transaction was disclosed in a filing with the SEC, which is available through this link.
Aevi Genomic Medicine, Inc. (NASDAQ GNMX) opened at 1.72 on Friday. The stock’s market cap is $63.83 million. Aevi Genomic Medicine, Inc. has a 12-month low of $0.98 and a 12-month high of $17.75. The company’s 50 day moving average price is $1.36 and its 200-day moving average price is $1.36.
WARNING: “Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) Director Sol J. Barer Buys 421,032 Shares” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.dispatchtribunal.com/2017/10/28/aevi-genomic-medicine-inc-gnmx-director-sol-j-barer-acquires-421032-shares.html.
A number of hedge funds and other institutional investors have recently bought and sold shares of GNMX. Teachers Advisors LLC bought a new position in Aevi Genomic Medicine in the 4th quarter worth about $204,000. TIAA CREF Investment Management LLC grew its position in Aevi Genomic Medicine by 16.7% in the 1st quarter. TIAA CREF Investment Management LLC now owns 97,719 shares of the biotechnology company’s stock worth $182,000 after purchasing an additional 13,966 shares during the last quarter. LMR Partners LLP bought a new position in Aevi Genomic Medicine in the 2nd quarter worth about $149,000. Birchview Capital LP grew its position in Aevi Genomic Medicine by 88.2% in the 2nd quarter. Birchview Capital LP now owns 128,000 shares of the biotechnology company’s stock worth $170,000 after purchasing an additional 60,000 shares during the last quarter. Finally, Northern Capital Management LLC grew its position in Aevi Genomic Medicine by 317.9% in the 2nd quarter. Northern Capital Management LLC now owns 106,050 shares of the biotechnology company’s stock worth $141,000 after purchasing an additional 80,675 shares during the last quarter. Hedge funds and other institutional investors own 20.82% of the company’s stock.
A number of equities analysts recently issued reports on the company. Needham & Company LLC lowered their price target on Aevi Genomic Medicine from $9.00 to $7.00 and set a “buy” rating on the stock in a report on Wednesday, August 16th. Jefferies Group LLC reissued a “hold” rating and set a $1.50 price target on shares of Aevi Genomic Medicine in a report on Monday, August 7th.
About Aevi Genomic Medicine
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohns disease.
Receive News & Ratings for Aevi Genomic Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.